Search peptides, terms, sources/
Hormonal signalling

Teriparatide

34-amino-acid fragment of parathyroid hormone, studied for osteoporosis. UK prescription-only medicine; trials looked at spine and hip fractures.

UK status and evidence last reviewed .

Evidence grade: best single recorded finding

How grading works

Best recorded finding: Strong evidence (level 4 of 4 on our scale)

This grades the evidence behind one recorded finding. It does not rate the medicine.

2 findings at this grade. See all findings

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations, and none of them means a product is safe to obtain or use.

UK status
Licensed UK medicineChecked
Best study type
Human trials3 human trials

What is Teriparatide?

Teriparatide is the 34-amino-acid active fragment of human parathyroid hormone, studied as a bone-building treatment for osteoporosis. In the UK it is a licensed prescription-only medicine, and large randomised trials found fewer vertebral fractures than with placebo or risedronate, but the UK product information says hip fractures are not significantly reduced.

Its UK licence covers osteoporosis in postmenopausal women and in men at increased risk of fracture, and osteoporosis linked to long-term glucocorticoid treatment.

Class
Parathyroid hormone receptor agonist (bone-anabolic)
Origin
Fragment / derived
Research areas
Bone Health Research
UK status
Licensed UK medicine
Best study type
Human trials
Evidence last reviewed

How does Teriparatide work?

According to the UK product information, teriparatide acts directly on osteoblasts, the cells that build new bone. It also raises calcium uptake from the gut and calcium reabsorption in the kidney indirectly. Given as an injection, it favours bone formation over bone breakdown, so it is called a bone-building treatment.

The mechanism in more detail

Teriparatide is the 1-34 fragment of parathyroid hormone. According to the UK product information, it stimulates bone formation by acting directly on osteoblasts, the cells that build new bone. It also raises calcium absorption in the gut and calcium reabsorption in the kidney indirectly.

Parathyroid hormone can either build bone or break it down, depending on the pattern of exposure. The product information states that teriparatide, given as an injection, increases new bone formation on both trabecular (spongy) and cortical (outer) bone surfaces and favours osteoblast activity over osteoclast activity. This is the reason it is described as an anabolic (bone-building) osteoporosis treatment, in contrast to drugs that mainly slow bone loss.

This mechanism account is taken from the UK product information (the SmPC), a regulator-approved manufacturer document, rather than from a single primary structural-biology study.

Classification and structure

Names
Teriparatide; Forsteo (UK brand name); parathyroid hormone (1-34); PTH(1-34)
Class
Parathyroid hormone receptor agonist (bone-anabolic)
Origin
Fragment / derived
Structure
34-amino-acid fragment corresponding to residues 1 to 34 of human parathyroid hormone, described in the UK product information as the active fragment of the endogenous hormone.
Routes used in the research
Subcutaneous injection in the trials cited.How the substance was given in the studies cited on this page. This describes study methods only. It is not guidance on use.

What does the research show?

Teriparatide has 5 recorded research findings. Each shows how strong it is, the kind of study behind it, its source and its main limitation.

Findings by strength of evidence

5 findings

Counts recorded findings by grade. It does not rate the medicine.

Findings by strength of evidence
PreliminaryLimitedModerateStrongNot graded
00122

Fractures versus placebo Strong

In a randomised, placebo-controlled trial of 1,637 postmenopausal women who already had vertebral fractures, new vertebral fractures occurred in 14% of the placebo group and in 5% and 4% of the two teriparatide groups (relative risks about 0.35 and 0.31) over a median of 21 months. Non-vertebral fragility fractures occurred in 6% of the placebo group and 3% in each teriparatide group. Lumbar spine bone mineral density rose by 9 and 13 percentage points more than with placebo. The authors reported only minor side effects, mainly occasional nausea and headache.

Study type
Human trial
Population
1,637 postmenopausal women with prior vertebral fractures; randomised, double-blind, placebo-controlled; subcutaneous injection.
Source
1 Neer et al., 2001

Limitation: Placebo-controlled, so it does not compare teriparatide with other osteoporosis drugs.

Limitations in full

Placebo-controlled, so it does not compare teriparatide with other osteoporosis drugs. Women had prior vertebral fractures, so results may not apply to lower-risk groups. In the higher-strength group, forearm (radial shaft) bone density was lower than with placebo.

Teriparatide versus risedronate (VERO) Strong

In the VERO trial, postmenopausal women with severe osteoporosis were randomised to teriparatide or the bisphosphonate risedronate. At 24 months, new vertebral fractures occurred in 28 women (5.4%) on teriparatide and 64 (12.0%) on risedronate (relative risk 0.44, 95% CI 0.29 to 0.68). Clinical fractures occurred in 30 (4.8%) versus 61 (9.8%) (hazard ratio 0.48, 95% CI 0.32 to 0.74). The difference in non-vertebral fragility fractures (4.0% versus 6.1%) was not statistically significant (hazard ratio 0.66, 95% CI 0.39 to 1.10).

Study type
Human trial
Population
Postmenopausal women with severe osteoporosis; multicentre, double-blind, double-dummy; 1,360 women (680 per group) in secondary VERO analyses.
Source
2 Kendler et al., 2018

Limitation: Only one comparator drug (risedronate).

Limitations in full

Only one comparator drug (risedronate). Non-vertebral fracture difference was not statistically significant, so the result applies mainly to vertebral and clinical fractures.

Glucocorticoid-induced osteoporosis Moderate

In 428 adults with osteoporosis linked to glucocorticoid treatment, teriparatide was compared with alendronate. Lumbar spine bone mineral density rose 7.2% with teriparatide versus 3.4% with alendronate, and new vertebral fractures were 0.6% versus 6.1%. Non-vertebral fractures were 5.6% versus 3.7%, a difference that was not statistically significant.

Study type
Human trial
Population
428 adults with glucocorticoid-induced osteoporosis; randomised comparison with alendronate.
Source
3 Saag et al., 2007

Limitation: Active-comparator trial with no placebo group.

Limitations in full

Active-comparator trial with no placebo group. Fracture numbers were small, and non-vertebral fractures did not differ significantly.

Hip fractures not shown to fall Not graded

The UK product information states that in postmenopausal women teriparatide significantly reduces vertebral and non-vertebral fractures, but that hip fractures are not significantly reduced.

Study type
Regulatory-clinical source
Population
Not applicable; regulator-approved product information.
Source
4 eMC, 2026

Limitation: A summary statement from the manufacturer's regulator-approved text, not a separate analysis.

Mechanism of action Not graded

Teriparatide is the active 1-34 fragment of parathyroid hormone. It stimulates bone formation by acting directly on osteoblasts and indirectly raises calcium absorption in the gut and calcium reabsorption in the kidney. Given as an injection, it favours bone formation over bone breakdown.

Study type
Regulatory-clinical source
Population
Pharmacology summary, not a single clinical population.
Source
4 eMC, 2026

Limitation: Mechanism statement from the manufacturer's product information, not a standalone graded claim.

What safety findings have been reported?

3 safety findings are recorded for Teriparatide. A short list does not mean a substance is safe; it reflects what has been studied and reported.

Osteosarcoma in rats

In rats given injections for close to a lifetime, teriparatide caused exaggerated bone formation and more osteosarcomas (bone tumours). The UK product information regards the relevance to humans as probably minor, given differences in bone physiology, and notes that no bone tumours were seen in ovariectomised monkeys and no osteosarcomas were observed in clinical trials or the post-treatment follow-up study. Treatment length is limited because of this finding.

Source
4 eMC, 2026

Post-marketing osteosarcoma surveillance

A 15-year US post-marketing surveillance study identified 3 osteosarcoma cases among teriparatide-exposed patients against 4.17 expected from background rates (standardised incidence ratio 0.72, 90% CI 0.20 to 1.86), so it detected no increase.

Source
5 Gilsenan et al., 2021

Calcium, blood pressure and common reactions

The UK product information describes slight, transient rises in serum calcium, and isolated transient episodes of low blood pressure on standing, mostly in the first few injections, which resolved on lying down. It advises caution in people with active or recent kidney stones and in moderate kidney impairment. The most common adverse reactions are nausea and pain in the limb, with headache and dizziness also reported.

Source
4 eMC, 2026

What is Teriparatide's UK regulatory status?

Marketing authorisation
Licensed in the UK. The electronic Medicines Compendium lists Forsteo solution for injection in a pre-filled pen, with Eli Lilly Nederland B.V. named as the marketing authorisation holder.
Prescription status
Prescription-only medicine (POM).
Medicine class
Licensed medicinal product.
MHRA position
Teriparatide appears on the MHRA Products database active-substance index (checked 14 November 2026). The eMC product record was last updated on 24 February 2026 and the product information text was revised on 27 January 2026.
Authorised use
Treatment of osteoporosis in adults who are postmenopausal women or men at increased risk of fracture (in postmenopausal women, vertebral and non-vertebral fractures are significantly reduced, but hip fractures are not); and treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk of fracture.
Other restrictions
NHS funding decisions are separate from the marketing authorisation.

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations, and none of them means a product is safe to obtain or use.

References

5 sources, numbered as cited above. Each has its own page with its limitations and everything that cites it.

  1. Neer RM, Arnaud CD, Zanchetta JR, et al. (2001). Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal of MedicineHuman clinical trial, RCT · DOI 10.1056/NEJM200105103441904 · PMID 11346808 · Original ↗
  2. Kendler DL, Marin F, Zerbini CAF, et al. (2018). Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. The LancetHuman clinical trial, RCT · DOI 10.1016/S0140-6736(17)32137-2 · PMID 29129436 · Original ↗
  3. Saag KG, Shane E, Boonen S, et al. (2007). Teriparatide or alendronate in glucocorticoid-induced osteoporosis. New England Journal of MedicineHuman clinical trial, RCT · DOI 10.1056/NEJMoa071408 · PMID 18003959 · Original ↗
  4. Eli Lilly Nederland B.V. (marketing authorisation holder); Eli Lilly and Company Limited (company listed on eMC) (2026). Forsteo solution for injection in pre-filled pen (teriparatide): Summary of Product Characteristics. electronic Medicines Compendium (eMC) · Original ↗
  5. Gilsenan A, et al. (2021). Teriparatide Did Not Increase Adult Osteosarcoma Incidence in a 15-Year US Postmarketing Surveillance Study. Journal of Bone and Mineral ResearchHuman observational · DOI 10.1002/jbmr.4188 · PMID 32990990 · Original ↗

Questions about Teriparatide

What is Teriparatide?

Teriparatide is the 34-amino-acid active fragment of human parathyroid hormone, studied as a bone-building treatment for osteoporosis. In the UK it is a licensed prescription-only medicine, and large randomised trials found fewer vertebral fractures than with placebo or risedronate, but the UK product information says hip fractures are not significantly reduced. Read what it is.

Is Teriparatide licensed in the UK?

PeptGuru records Teriparatide's UK status as: Licensed UK medicine. The licensed products and their approved uses are listed in the UK status section. UK status checked 14 November 2026. This is a record of regulation, not a recommendation. Read the UK status.

What does the research on Teriparatide show?

PeptGuru records 5 research findings for Teriparatide: 3 from human trials and 2 from regulatory or other records. Each finding has its own evidence grade, source and main limitation. Read the research findings.

What safety findings have been reported for Teriparatide?

3 safety findings are recorded, including: osteosarcoma in rats; post-marketing osteosarcoma surveillance; calcium, blood pressure and common reactions. Each is cited to its source. A short list does not mean a substance is safe. Read the safety findings.

Where are the sources for Teriparatide?

All 5 sources are listed in the references, each with a link to the original study or regulator document and its own source page on PeptGuru. See the references.

Review record and change log

Last reviewed
Evidence last reviewed
UK status checked
Reviewed by
PeptGuru editorial team
  • New profile · Teriparatide added: 5 findings and 3 safety items, each checked against its published record, with UK status checked on the MHRA register.

How findings are graded: the grading method. All changes.

  • Abaloparatide

    Synthetic 34-amino-acid peptide modelled on PTHrP, studied for osteoporosis. UK prescription-only medicine; the main trial compared it with placebo.

    Hormonal signallingHuman trialsEvidence reviewed
    StrongLicensed UK medicine
  • KisspeptinMetastin

    Natural reproductive hormone studied in UK trials for low sexual desire and IVF egg maturation. No UK marketing authorisation identified.

    Hormonal signallingHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • Oxytocin

    Natural hormone licensed in the UK for obstetric use; studied separately for social cognition, with mostly negative trial results.

    Hormonal signallingHuman trialsEvidence reviewed
    LimitedLicensed for a different use

Compare Teriparatide with Abaloparatide

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.